Sign In
Buy KHTRF
$5.99
+0.0800 (+1.35%)
At Close: Jun 03, 2026
Knight Announces Closing of US$100 Million Revolving Credit Facility
05:15pm, Friday, 31'st Oct 2025
MONTREAL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, announced today that it has cl
Notice of Knight Therapeutics' Third Quarter 2025 Results Conference Call
07:30am, Thursday, 30'th Oct 2025
MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2025 financial
Knight Therapeutics Announces Relaunch of ORGOVYX® in Canada
07:30am, Tuesday, 07'th Oct 2025
MONTREAL, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has relaunched ORGOVYX® (
Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada
07:30am, Tuesday, 07'th Oct 2025
MONTREAL, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has relaunched MYFEMBR
Knight Therapeutics Inc. places No. 384 on The Globe and Mail's seventh annual ranking of Canada's Top Growing Companies
09:18am, Friday, 26'th Sep 2025
MONTREAL, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it has ranked No. 384 on the 2025 Report on Business magazine
Knight Therapeutics Inc. (KHTRF) Q2 2025 Earnings Call Transcript
01:23am, Friday, 08'th Aug 2025
Knight Therapeutics Inc. (OTCPK:KHTRF) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Amal Khouri - Chief Business Officer Arvind Utchanah - Chief Financial Officer Sa
Knight Therapeutics Reports Second Quarter 2025 Results
07:30am, Thursday, 07'th Aug 2025
Achieved record-high quarterly revenues since inception Increased 2025 financial guidance
Notice of Knight Therapeutics' Second Quarter 2025 Results Conference Call
07:30am, Friday, 01'st Aug 2025
MONTREAL, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2025 financial
Knight Therapeutics Announces Closing of Previously Announced Acquisition of Paladin
09:11am, Tuesday, 17'th Jun 2025
MONTREAL, June 17, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today that it has completed the acquisiti
Knight Therapeutics and Sumitomo Pharma enter into Exclusive Licensing Agreements to commercialize Sumitomo's Canadian Portfolio
06:45am, Thursday, 05'th Jun 2025
MONTREAL and MARLBOROUGH, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, and Sumitomo Pharma America
Knight Therapeutics Inc. (KHTRF) Q1 2025 Earnings Call Transcript
03:30am, Sunday, 11'th May 2025
Knight Therapeutics Inc. (OTCPK:KHTRF) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Samira Sakhia – President and Chief Executive Officer Arvind Utchanah – Chief Fi
Knight Therapeutics Reports First Quarter 2025 Results
07:30am, Thursday, 08'th May 2025
MONTREAL, May 08, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today reported financial result
Knight Therapeutics Inc. announces voting results from the Annual General Meeting
05:10pm, Wednesday, 07'th May 2025
MONTREAL, May 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a pan-American (ex-US) specialty pharmaceutical company, announced today the voting result
Knight Therapeutics Announces Relaunch of ONICIT® in Brazil and Mexico
07:30am, Wednesday, 07'th May 2025
MONTREAL, May 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that has assumed full commercial ac
Notice of Knight Therapeutics' First Quarter 2025 Results Conference Call
07:30am, Thursday, 01'st May 2025
MONTREAL, May 01, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2025 financial r
